← All Nanonews

Nano1Health develops a genomic analysis platform for Leishmania infantum in a Neotec project

Funding 19 January 2022

Leishmania infantum amastigotes in a macrophage
Working with samples in the biosafety cabinet

Nano1Health received a NEOTEC grant from CDTI (SNEO20211355) to build a simple, agile platform for sequencing the Leishmania infantum genome and detecting markers of pathogenicity and drug resistance.

Every year around 400,000 dogs are infected in Spain and more than a thousand human cases are reported. No treatment is fully effective in dogs, the parasite can become resistant to a drug also used in people, and current diagnostics only confirm that the parasite is present.

The project has two goals: to identify biomarkers of pathogenicity and drug resistance for veterinary clinicians and biomedical and pharmaceutical companies, and to support molecular epidemiology studies comparing strains from animals and humans.

Questions about this news? Write to info@nano1health.com.